UniQure pulls first EU gene therapy – PMLiVE
|
UniQure pulls first EU gene therapy
PMLiVE Dutch biotech UniQure made headlines in 2012 when it won approval for its Glybera gene therapy, which at more than €1m is the world’s most expensive drug. Now just five years later, it is pulling it off the market. UniQure said there was simply not … |
|
Results of glioblastoma clinical trial show safety and clinical benefit of CAR T cell therapy
Medical Xpress CAR T cells are T cells – a type of immune cells involved in the defense against tumors – that have been programmed to recognize and kill tumor cells carrying one specific antigen, in this case HER2, on the surface of cancer cells through an artificial … |
STAT |
Gene therapy 1.0 is a flop, but biotech isn’t worried
STAT he Western world’s first gene therapy is soon to become but a footnote in biotech history, doomed by minuscule demand and a colossal price. But its failure has hardly dampened the enthusiasm of the scientists and biotech companies betting that gene … |
NBCNews.com |
First Gene Therapy Ever Approved Calling it Quits
Rare Disease Report It is not clear if the low demand is due to insurance companies saying no to the price tag or the fact that many of the FCS patients that can get the gene therapy already got it in the clinical trials. FCS is an extremely rare condition – affecting … Firm Pulls World’s First Gene Therapy Treatment: No One Wants ItNBCNews.com UniQure to Yank Pioneering Gene Therapy From Market in EuropeXconomy Hard-fought approval to commercial flop: Uniqure pulls plug on gene therapyBioWorld Online MedPage Today –FiercePharma –Labiotech.eu (blog) all 17 news articles » |
Business Insider |
Biotech firm pulls pioneering gene therapy due to no demand
Business Insider LONDON, April 20 (Reuters) – The biotech company behind the Western world’s first gene therapy and the most expensive prescription medicine in history is giving up on the product because of lack of demand. Only one patient has been treated commercially … First Gene Therapy Ever Approved Calling it QuitsRare Disease Report UniQure to Yank Pioneering Gene Therapy From Market in EuropeXconomy Hard-fought approval to commercial flop: Uniqure pulls plug on gene therapyBioWorld Online Managed Care magazine –FiercePharma –MedPage Today all 17 news articles » |
|
Hard-fought approval to commercial flop: Uniqure pulling plug on first gene therapy
BioWorld Online LONDON – Uniqure NV is ditching its world-first gene therapy Glybera and will not renew the European license when it expires on Oct. 25. If that is a sad end to one of the most protracted drug development sagas in history, it undoubtedly sets a bad … |